The only mistake by the prior management was that it didn’t apply for all 3 licences at once.
If it had,things would have been far more advanced re share price.
I think my summation of the Bioxyne situation was pretty accurate to be honest.
My main concern is that the management should remain focussed on taking the best options for THC and that isn’t the case when it sits on information for some reason before releasing to the market.
The management should act transparently in all its actions, rather than remain too secretive.
The share price gets hit lower when managenent doesn’t proceed with business diligently.
- Forums
- ASX - By Stock
- EPN
- THC Management Revisited Mark II
EPN
epsilon healthcare limited
Add to My Watchlist
0.00%
!
2.4¢

THC Management Revisited Mark II, page-3
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.288M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
EPN (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online